Equities Analysts Issue Forecasts for DNLI FY2025 Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI) – Equities researchers at B. Riley boosted their FY2025 earnings estimates for shares of Denali Therapeutics in a research report issued on Thursday, November 13th. B. Riley analyst M. Mamtani now forecasts that the company will earn ($3.02) per share for the year, up from their prior estimate of ($3.08). The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share. B. Riley also issued estimates for Denali Therapeutics’ FY2026 earnings at ($3.24) EPS, FY2027 earnings at ($2.48) EPS, FY2028 earnings at $1.98 EPS and FY2029 earnings at ($0.80) EPS.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.74) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.02. During the same quarter in the prior year, the firm earned ($0.63) earnings per share. The firm’s revenue for the quarter was up .0% compared to the same quarter last year.

DNLI has been the subject of several other reports. TD Cowen upgraded Denali Therapeutics to a “strong-buy” rating in a research report on Monday, July 28th. Morgan Stanley reduced their price target on shares of Denali Therapeutics from $33.00 to $30.00 and set an “overweight” rating on the stock in a research note on Monday, August 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Denali Therapeutics in a report on Wednesday, October 8th. Cantor Fitzgerald reissued an “overweight” rating on shares of Denali Therapeutics in a research note on Monday, September 8th. Finally, Stifel Nicolaus set a $37.00 target price on shares of Denali Therapeutics in a research report on Monday. Three analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $32.64.

Denali Therapeutics Trading Up 0.6%

Shares of DNLI stock opened at $17.48 on Monday. Denali Therapeutics has a fifty-two week low of $10.57 and a fifty-two week high of $26.18. The stock’s fifty day moving average price is $15.34 and its two-hundred day moving average price is $14.73. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.79 and a current ratio of 9.79. The company has a market cap of $2.56 billion, a PE ratio of -6.01 and a beta of 1.39.

Hedge Funds Weigh In On Denali Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Headlands Technologies LLC bought a new position in Denali Therapeutics during the 2nd quarter worth $26,000. Caitong International Asset Management Co. Ltd increased its stake in shares of Denali Therapeutics by 277.0% in the first quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company’s stock valued at $29,000 after buying an additional 1,551 shares during the period. Johnson Financial Group Inc. bought a new position in shares of Denali Therapeutics during the third quarter worth about $29,000. State of Wyoming acquired a new position in shares of Denali Therapeutics in the second quarter worth approximately $29,000. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of Denali Therapeutics in the first quarter worth approximately $41,000. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.